Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2025 Aug 27;133(6):912. doi: 10.1038/s41416-025-03077-3

Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma

Kaiqi Lan 1,2,#, Shibing Li 3,#, Guodong Jia 1,2,#, Suchen Li 1,2, Siyi Xie 1,2, Linquan Tang 1,2, Haiqiang Mai 1,2,, Li Yuan 1,2,
PMCID: PMC12449451  PMID: 40866613

Correction to: British Journal of Cancer 10.1038/s41416-025-03044-y, published online 12 May 2025

Following publication of the article, the authors noticed two small errors introduced during the typesetting process of the article. Firstly, figures were inadvertently published in black/white, rather than in colour. Secondly, a label within Figure 3 was adjusted in error during the typesetting process; the upper-scale label in Figure 3a, for EBV DNA, should have read “≥4000 copies/mL”, not “4000 copies/mL”. The figure has been corrected.

graphic file with name 41416_2025_3077_Figa_HTML.jpg

The original article has been corrected.

Contributor Information

Haiqiang Mai, Email: maihq@mail.sysu.edu.cn.

Li Yuan, Email: yuanli@sysucc.org.cn.


Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES